Lung Cancer

The FDA has given the go-ahead to a combination of tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for patients with non-small cell lung cancer and no EGFR mutations or ALK aberrations.

Immunotherapy has changed the face of cancer treatment, but requires appropriate irAE management to reach full potential.

Cemiplimab, in combination with platinum-based chemotherapy, has been approved for patients with advanced non–small cell lung cancer with no EGFR, ALK, or ROS1 aberrations.

After demonstrating significant efficacy as a third-line treatment for patients with metastatic HER2-positive breast cancer, fam-trastuzumab deruxtecan-nxki has gained approval from the FDA for 5 indications and is under investigation across solid tumors.

A quality improvement project improved the time to molecular testing for patients with newly diagnosed, metastatic non–small cell lung cancer.

After 13.1 months of follow-up, the median progression-free survival in patients with EGFR-mutant non–small cell lung cancer who received a sintilimab-based regimen was 5.5 months.

Selpercatinib demonstrated a promising efficacy profile in patients with RET-fusion positive solid tumors.

Phase 2 findings indicate that a combination of avelumab and axitinib may draw promising responses in patients with advanced type B3 thymoma and thymic carcinoma.

Structured preceptorships promote competence, confidence, and job satisfaction in new oncology nurse practitioners.

On September 22 and 23, 2022, the FDA’s Oncologic Drugs Advisory Committee (ODAC) convened for a hearing to assess the risk-benefit ratio of 3 agents.

Selpercatinib was approved by the FDA for RET fusion–positive non–small cell lung cancer and locally advanced or metastatic RET fusion–positive solid tumors.

Sotorasib doubled the progression-free survival rate in patients with KRAS G12C–mutated non–small cell lung cancer.

Julie Malo, CCRP, a research nurse with the University of Montreal, discusses a nurse-directed initiative examining how the gut microbiome affects immune checkpoint blockade responses in patients with non–small cell lung cancer.

Kelly Goodwin, MSN, RN, ANP-BC, discusses the significance of the recent FDA approvals of capmatinib and trastuzumab deruxtecan for patients with non–small cell lung cancer.

Findings from the SHAWL study found that sexual dysfunction rates are high among women with lung cancer.

Compared with gefitinib monotherapy, a combo regimen of gefitinib plus chemotherapy generated superior time to second progression in untreated non–small cell lung cancer.

Best management strategies for vancomycin infusion reactions may include premedication, infusion-rate adjustment, and, in some cases, alternative antibiotic therapy.

Sotorasib is often associated with a high rate of hepatotoxic events, most of which are from elevated liver enzymes. However, a lead-in dosing strategy may help address this adverse event and improve patient tolerability.

A study presented at the 2022 World Conference on Lung Cancer explored the experiences of patients who received checkpoint inhibition therapy for non–small cell lung cancer.

Hearing loss for cancer survivors is largely underreported, but once identified, is easily treatable, according to Christine Miaskowski, PhD, RN.

Patients with treatment-naive extensive-stage small cell lung cancer showed encouraging clinical responses with pembrolizumab and etoposide after multiple years of follow-up.

Phase 3 findings from the IMpower010 trial show that patients with resected non–small cell lung cancer may achieve an overall survival benefit with atezolizumab.

Extended follow-up data from 2 trials confirmed that larotrectinib yielded positive progression-free and overall survival outcomes for patients with NTRK-positive lung cancer.

Phase 1 findings showed a 50% overall response rate among patients with EGFR-mutated non–small cell lung cancer who received amivantamab in combination with lazertinib plus carboplatin and pemetrexed.

The FDA has approved trastuzumab deruxtecan for patients with HER2-mutated non–small cell lung cancer after the DESTINY-Lung02 results demonstrated a 57% overall response rate with the agent. The drug comes with warning for interstitial lung disease, neutropenia, and left ventricular dysfunction.

The FDA has granted capmatinib regular approval for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have a mutation leading to MET exon 14 skipping. The drug comes with warning for pneumonitis, hepatotoxicity, and pancreatic toxicity.

Patients with previously treated non–small cell lung cancer experienced a median overall survival of 16.9 months with second- or third-line tislelizumab vs 11.9 months with docetaxel.

The FDA has scheduled 3 sessions for the Oncologic Drugs Advisory Committee to review updates on the new drug application for poziotinib tablets and data for the continued approval of indications for melphalan flufenamide and duvelisib.

At the 6th Annual SONO meeting, Beth Sandy, MSN, CRNP, reviewed available treatment options for patients with identified driver mutations in non–small cell lung cancer.

Faith Mutale, CRNP, discusses the paradigm shift needed in oncology to address clinical trial enrollment hesitancy among African American patients with lung cancer.